IgA Nephropathy: Prognosis and Current Therapies in 2026

What IgA Nephropathy Really Does to Your Kidneys

IgA Nephropathy, sometimes called Berger’s disease, isn’t just a lab result. It’s an autoimmune attack on your kidneys. Your body makes too much of a faulty version of IgA, an antibody meant to fight infections. Instead of clearing out, this abnormal IgA clumps together with other proteins and gets stuck in the filtering units of your kidneys-the glomeruli. That’s when inflammation starts. Over time, these tiny filters scar, leak blood and protein into your urine, and slowly lose function. It’s not sudden. It creeps in. Many people don’t know they have it until they notice dark, tea-colored urine after a cold or sore throat-or until a routine blood test shows protein or blood in their urine.

It hits hardest in people between their teens and early 40s. In Asia, it’s the most common cause of kidney failure in young adults. In Western countries, it’s still the #1 form of primary glomerulonephritis. About 25% to 50% of all cases of this type of kidney disease are IgA Nephropathy. And here’s the hard truth: up to half of people with persistent proteinuria will lose kidney function within 10 to 20 years. That’s not a guess. That’s what registries show.

The New Rules: KDIGO 2025 Changed Everything

Before 2025, doctors treated IgA Nephropathy like a slow drip. Start with blood pressure meds-usually ACE inhibitors or ARBs-and wait three months to see if proteinuria drops. Only then, if it didn’t, would they consider steroids or other immune drugs. That waiting period? It was a mistake. While you waited, the IgA deposits kept damaging your kidneys. The KDIGO 2025 guidelines ended that. Now, if you’re at high risk, you start both types of treatment at the same time.

This isn’t just a tweak. It’s a full reset. The old approach assumed that lowering blood pressure and proteinuria alone would stop the disease. But IgA Nephropathy has its own engine-the abnormal IgA production. You need to shut that down and protect your kidneys from the damage it causes. That’s why the new guidelines say: treat the cause and the consequence, together.

What “High Risk” Really Means Now

You can’t treat everyone the same. The 2025 guidelines use a risk calculator that looks at four things: how much protein you’re losing in your urine, your blood pressure, your kidney function (eGFR), and what your kidney biopsy shows (the MEST-C score). If you’re losing more than 0.75 grams of protein per day and have high blood pressure or low kidney function, you’re in the high-risk group. Even if your proteinuria is between 0.5 and 0.75 g/day, but your biopsy shows scarring (mesangial hypercellularity or endocapillary proliferation), you’re still considered high risk.

This shift matters because proteinuria used to be the only number that mattered. Now we know that even patients with proteinuria under 0.88 g/g creatinine can still reach kidney failure within 10 years. That’s why the new target isn’t just under 1 gram-it’s under 0.5 grams per day. It’s aggressive. It’s not easy. But data shows it’s necessary.

The Four Main Treatments You Need to Know

There are now four pillars of treatment, and which ones you get depends on your risk, your location, and your tolerance for side effects.

1. RAS inhibitors (ACEi/ARBs) - These are the foundation. They lower blood pressure and reduce protein leakage. Most patients take these anyway. But now, they’re not optional-they’re mandatory from day one.
2. SGLT2 inhibitors - Originally for diabetes, these drugs (like dapagliflozin) also protect kidneys in non-diabetic patients. They reduce filtration pressure and slow decline. Used with RASi, they’ve been shown to cut kidney failure risk by 30% in IgAN patients.
3. Nefecon - This is the first drug approved specifically for IgA Nephropathy (FDA, December 2023). It’s a targeted-release steroid that releases budesonide in the gut, where abnormal IgA is made. It doesn’t flood your whole body with steroids. In trials, it cut proteinuria by 30-40% and slowed kidney decline by 40% over two years. Side effects? Mostly mild-sore throat, headache. But it costs $125,000 a year in the U.S. Insurance fights are common.
4. Systemic glucocorticoids - Still used, especially where Nefecon isn’t available. But they’re a blunt tool. Weight gain, mood swings, bone loss, diabetes risk-these are real. The new guidelines recommend short, low-dose courses (like 0.6 mg/kg for 2 months, then taper) to reduce harm. They’re effective, but only if you can tolerate them.

Some regions have their own standards. In Japan, tonsillectomy is common-removing the tonsils reduces IgA triggers from throat infections. In China, mycophenolate mofetil and hydroxychloroquine are used more often than steroids. But outside those regions, the evidence isn’t strong enough to make them standard.

What’s on the Horizon? The Next Five Years

The future of IgA Nephropathy isn’t just about more drugs-it’s about smarter drugs. Right now, we guess who will respond. In five years, we might know. Several biomarkers are being tested: levels of galactose-deficient IgA1, antibodies against it, and complement proteins. If these pan out, we’ll be able to say: “Your IgA profile matches this pathway-so we’ll use this drug.”

Three new drugs are in phase 3 trials right now. One blocks APRIL, a protein that tells immune cells to make bad IgA. Another targets the complement system, which amplifies kidney damage. A third, sparsentan (approved in Europe in 2024), blocks both endothelin and angiotensin-two systems that raise pressure in the glomeruli. It’s already showing better proteinuria reduction than RASi alone.

And then there’s the big question: Can we stop the disease before it starts? Researchers are now looking at early signs in healthy people with family history or recurrent hematuria. Could we intervene before proteinuria even appears? That’s the next frontier.

The Real-World Struggle: Cost, Access, and Burnout

Here’s the gap between guidelines and reality. In the U.S., 68% of patients trying Nefecon get denied by insurance at first. Many need to file appeals, sometimes with letters from their nephrologist, lab results, and proof of failed alternatives. The process can take months. By then, some patients lose hope-or just give up.

Patients on combination therapy-RASi, SGLT2i, Nefecon, and maybe a steroid-are managing four pills a day, with different schedules. Some take them with food, others on empty stomach. Some need blood tests every month. It’s exhausting. A 16-year-old on Facebook told her group: “I hate taking so many pills. I feel like a lab rat.”

And it’s not just the U.S. In low- and middle-income countries, only 22% of patients get guideline-recommended care. Nefecon? Unavailable. SGLT2 inhibitors? Too expensive. Even ACE inhibitors aren’t always stocked. This isn’t just a medical problem-it’s a justice problem.

What You Can Do Right Now

If you have IgA Nephropathy, here’s what matters most:

• Track your numbers-proteinuria, blood pressure, eGFR. Write them down. Know your trend. If your proteinuria is still above 0.5 g/day after six months, ask your doctor why.
• Ask about Nefecon-even if you’re on steroids. It’s safer. Ask if your insurance covers it. If they say no, ask for the appeal process. Many patients win on second try.
• Don’t skip SGLT2 inhibitors-even if you’re not diabetic. They’re not just for blood sugar. They protect your kidneys.
• Know your biopsy-ask for a copy of your MEST-C score. If you have “C” (crescents) or “E” (endocapillary proliferation), you’re at higher risk. That changes your treatment plan.
• Join a patient group-the IgA Nephropathy Support Group on Facebook has over 8,500 people. They share insurance tips, side effect hacks, and emotional support.

The goal isn’t just to survive. It’s to live well. To work. To travel. To raise kids. To not be defined by your kidneys. The tools to do that exist now. The challenge is getting them to everyone who needs them.